A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn's Disease

down-regulation of smad7 with a specific smad7 antisense (AS) oligonucleotide-containing oral drug (mongersen) was effective in pre-clinical studies and initial clinical trials in crohn's disease (CD) patients. a recent phase 3 trial was discontinued due to an apparent inefficacy of the drug, but factors contributing to the failure of this study remain unknown. here, we analysed the frequency in CD of rs144204026 C/T single nucleotide polymorphism (SNP), which maps on the corresponding region targeted by the Smad7 AS contained in the mongersen formulation and examined whether such a variant allele affects the ability of smad7 AS to knockdown smad7.